One study reported aberrant RB pathway activity in 96% of high-grade CS cases, driven by decreased levels of p16 (48%), increased levels of CKD4 (55%), or elevated cyclin D1 levels (62%) [49]. This evidence concerns the gene CDKN2A and Cowden syndrome 1.